Therapy
Photopheresis therapy for cutaneous T-cell lymphoma

https://doi.org/10.1016/S0190-9622(96)90683-0Get rights and content

Abstract

Background: Cutaneous T-cell lymphoma is a chronic peripheral lymphoma in which aggressive combined therapy elicits high response rates but does not improve survival. Photopheresis therapy has reportedly induced remissions and prolonged survival in patients with advanced disease.

Objective: We studied all patients who began photopheresis treatment between February 1988 and July 1994 to determine whether we could confirm the remission rates of previous studies, to evaluate variables that might predict a response, and to discover whether an accelerated delivery system would improve the remission rate or response time.

Methods: After an oral dose of methoxalen was administered, a leukocyte-enhanced quantity of blood was exposed to UVA radiation for 1.5 hours and returned to the patient. With our accelerated system, 6 × 109 cells were irradiated in nine cycles. Treatments were given on 2 consecutive days once a month.

Results: Among 34 patients whose results could be evaluated, the overall response rate (complete and partial remissions) was 50%; most patients had mild side effects. All responders except one had erythroderma. Responders had a decrease of 75% in mean skin scores, whereas nonresponders had an increase of 21%.

Conclusion: Photopheresis appears to be effective for selected patients with erythrodermic cutaneous T-cell lymphoma, although we did not achieve as high a remission rate as previously reported by others.

References (27)

  • BA Pancake et al.

    The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease: a study of 50 patients

    J Clin Invest

    (1995)
  • R Edelson et al.

    Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy

    N Engl J Med

    (1987)
  • R Edelson et al.

    Photopheresis update

    Prog Dermatol

    (1991)
  • Cited by (133)

    • Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part II. Prognosis, management, and future directions

      2014, Journal of the American Academy of Dermatology
      Citation Excerpt :

      Later studies yielded a 35% to 71% ORR and a 14% to 26% CRR.122-126 Parameters associated with favorable response include short disease duration, clinical improvement in <6 months, normal CD8+ T cell count and CD4:CD8 ratio, low percentage of Sézary cells, and the absence of extracutaneous disease.122-127 Bexarotene or IFNα may be added for synergy.126,128-131

    • The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas

      2012, Transfusion and Apheresis Science
      Citation Excerpt :

      The pivotal study was followed by a number of other studies both from American and European centers. The most important clinical studies that used ECP as monotherapy are shown in Table 1 [2,11–17]. The review of the results of the clinical studies mentioned above inevitably raises concerns, discussed in the following paragraphs:

    View all citing articles on Scopus

    Supported in part by a Physicians' Referral Service grant from the M. D. Anderson Cancer Center and by the Burnell Chaney Patient Education Fund.

    View full text